DeCure for Posterior uveitis

In a 2016 study of 15 patients with posterior uveitis, vitreous samples were analysed with antibody arrays for 200 human cytokines. Unsupervised clustering based on cytokine expression revealed that specific protein networks and molecular pathways are altered in different forms of uveitis. A common cytokine signature in the vitreous included interleukin 23, IL-1 receptor I, IL-17R, tissue inhibitors of metalloproteinase 1 and 2, insulinlike growth factor-binding protein 2, nerve growth factor, platelet-derived growth factor receptor β polypeptide, bone morphogenic protein 4, and stem cell factor. In one patient with progressive idiopathic visual loss, the analysis pointed to retinal autoimmunity, confirmed by serum antibodies to S-arrestin. The authors state that personalised treatment reversed that patient’s visual loss, but the abstract gives no drug name, no sample size for the treatment effect, and no controlled data.

A 2023 literature review on paediatric infectious posterior uveitis lists cat-scratch disease, toxocariasis, tuberculosis, viral diseases, and toxoplasmosis as the most important causes. Ocular manifestations include retinitis, neuroretinitis, and choroidal or peripheral granulomas. The review stresses that infectious uveitis must be excluded before starting immunosuppressive therapy, but it provides no new trial data or patient numbers.

A 2016 prospective study in Nepal enrolled 180 new uveitis patients over 18 months. Mean visual acuity at presentation was 0.49 logMAR units, improving to 0.39 at week 1 and 0.35 at week 4, then deteriorating to 0.62 at week 6. Anterior and posterior uveitis patients showed significant improvement (p ≤ 0.001) on all three visual function scales; panuveitis and intermediate uveitis showed significant improvement on two scales. The effect size ranged from small to large. The abstract does not specify which treatments were given, and the visual deterioration at week 6 is unexplained.

A 2023 German article notes that intermediate and posterior uveitis have multiple infectious and noninfectious causes, and that posterior uveitis is clinically multifaceted. It states that some entities require prompt therapy to preserve vision but gives no new data. A separate 2023 case report describes a 48-year-old woman with ankylosing spondylitis on secukinumab who developed acute posterior multifocal placoid pigment epitheliopathy (APMPPE) in one eye, with yellow-white lesions and subfoveal fluid that regressed without scarring. This is a single case, not a trial.